

(51) International Patent Classification:
C12Q 1/68 (2006.01)(21) International Application Number:
PCT/US2011/045253(22) International Filing Date:
25 July 2011 (25.07.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/368,217 27 July 2010 (27.07.2010) US
61/414,310 16 November 2010 (16.11.2010) US
61/485,536 12 May 2011 (12.05.2011) US(71) Applicant (for all designated States except US): **GENOMIC HEALTH, INC.** [US/US]; 301 Penobscot Drive, Redwood City, CA 94063 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHAK, Steven** [US/US]; 648 Fairway Circle, Hillsborough, CA 94010 (US). **BAEHNER, Frederick, L.** [US/US]; 2090 Green Street, #46, San Francisco, CA 94123 (US). **MADDALA, Tara** [US/US]; 1166 Ribier Court, Sunnyvale, CA 94087 (US). **LEE, Mark** [US/US]; 14122 Amherst Court, Los Altos Hills, CA 94022-1801 (US). **PELHAM, Robert, J.** [US/US]; 2500 Carmelita Ave, Belmont, CA 94002 (US). **COWENS, Wayne** [US/US]; 16 Linda Vista, Tiburon, CA 94920 (US). **CHERBAVAZ, Diana** [US/US]; 125Merced Ave., San Francisco, CA 94127 (US). **KIEFER, Michael, C.** [US/US]; 4009 Terra Granada Dr. #1B, Walnut Creek, CA 94595 (US). **CRAGER, Michael** [US/US]; 63 Lorelei Lane, Menlo Park, CA 94025 (US). **GODDARD, Audrey** [US/US]; 72 Merced Avenue, San Francisco, CA 94127 (US). **BAKER, Joffe, B.** [US/US]; 1400 Avery Street, Montara, CA 94037 (US).(74) Agent: **FRANCIS, Carol, L.**; Bozicevic, Field & Francis LLP, 1900 University Avenue, Suite 200, East Palo Alto, CA 94303 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER

FIGURE 1



(57) Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with sequence listing part of description (Rule 5.2(a))*
GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*